Related Experiment Video
Updated: Jan 8, 2026
Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment
Published on: January 12, 2024
Cost-consequence Analysis of Secukinumab vs Adalimumab in Moderate-to-severe Hidradenitis Suppurativa
A Martorell Calatayud1, A Molina-Leyva2, A Jiménez Morales3
1Department of Dermatology, Hospital de Manises, Valencia, Spain.
Insights
Secukinumab is a more cost-effective biologic therapy for moderate-to-severe hidradenitis suppurativa (HS) in Spain compared to adalimumab. This analysis shows secukinumab offers lower costs per responder and better treatment adherence over one year.
Area of Science:
- Pharmacoeconomics
- Dermatology
- Health Technology Assessment
Background:
- Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition.
- Biologic therapies like adalimumab and secukinumab are used for moderate-to-severe HS.
- These treatments increase disease management costs within healthcare systems.
Purpose of the Study:
- To estimate the cost difference between secukinumab and adalimumab.
- To determine the cost per responding patient after one year of therapy.
- To evaluate treatments from the Spanish National Health System (NHS) perspective.
Main Methods:
- A decision tree model compared treatment sequences.
- Patient response was defined as ≥ 50% clinical improvement.
- Analysis considered only pharmacological costs in Euros (2023).
Main Results:
- Secukinumab treatment sequences cost €1,198,912 total, or €16,858 per responder.
- Adalimumab treatment costs were 2.5% higher, at €19,701 per responder.
- 80% of secukinumab responders maintained treatment versus 31% for adalimumab.
Conclusions:
- Secukinumab presents a more cost-efficient therapeutic option for moderate-to-severe HS.
- This financial assessment aids decision-making for the Spanish NHS.
- Secukinumab is a suitable choice for managing HS in the Spanish healthcare setting.
Background And Objective:
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease. Treatment for moderate-to-severe HS includes biologic therapies (adalimumab and secukinumab), resulting in increased disease management costs. Our aim was to estimate the difference between secukinumab and adalimumab in terms of pharmacological costs and costs per responding patient 1 year into therapy from the Spanish National Health System (NHS) perspective.
Material And Methods:
We designed a decision tree comparing different treatment sequences, starting with a different first-line therapy. Patients switched arms based on achieving HS clinical response ≥50% (based on the SUNSHINE, SUNRISE, and PIONEER clinical trials results). A cohort of 100 patients was considered. Only treatment costs in € (2023 base year) were considered for the analysis. A panel of experts validated the model structure and parameters.
Results:
After 52-weeks into therapy, treatment sequences in the secukinumab group resulted in a total cost of €1,198,912, corresponding to €16,858 per responder. Total costs in the adalimumab treatment group were 2.5% higher, corresponding to €19,701 per responder. A total of 80% of responders who start treatment with secukinumab do not change treatment, while only 31% of responders who start treatment with adalimumab stay on the same treatment.
Conclusions:
The results of our financial assessment can help decision makers in selecting the most efficient therapeutic approach for treating patients with moderate-to-severe HS and poses secukinumab as a suitable therapeutic option for the Spanish NHS.
